February 2019 - Clinical trial listings - geography, diseases, sponsors -

Clinical Trials for Niacin

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial
Trial ID	Title	Status	Sponsor	Phase	Summary
NCT00000482	Coronary Drug Project	Completed	National Heart, Lung, and Blood Institute (NHLBI)	Phase 3	To determine whether regular administration of lipid modifying drugs (clofibrate, nicotinic acid, estrogen, dextrothyroxine) to men with a documented myocardial infarction would result in significant reduction in total mortality over a five year period. Secondarily, to determine whether the degree to which these drugs changed serum lipids was correlated with any effect on mortality and morbidity rates; to gain further information on the long-term prognosis of myocardial infarction (by studying the control group as intensively as the treatment group); to acquire further experience and knowledge concerning the techniques and methodology of long-term clinical trials; to determine, in a substudy, the effectiveness of aspirin, a platelet inhibitor, in reducing recurrences of myocardial infarction.
NCT00000512	Familial Atherosclerosis Treatment Study	Completed	National Heart, Lung, and Blood Institute (NHLBI)	Phase 3	To compare the effects of two intensive lipid-lowering regimens with conventional therapy on coronary atherosclerosis as assessed by arteriography.
NCT00000512	Familial Atherosclerosis Treatment Study	Completed	University of Washington	Phase 3	To compare the effects of two intensive lipid-lowering regimens with conventional therapy on coronary atherosclerosis as assessed by arteriography.
NCT00000539	Arterial Disease Multifactorial Intervention Trial (ADMIT)	Completed	National Heart, Lung, and Blood Institute (NHLBI)	Phase 3	To evaluate, in asymptomatic and symptomatic participants with peripheral arterial disease, the feasibility of recruitment and adherence, efficacy and safety of HDL-C raising along with effective control of LDL-C levels, antioxidant therapy, antithrombotic therapy, and their combinations.
NCT00000553	HDL-Atherosclerosis Treatment Study (HATS)	Completed	National Heart, Lung, and Blood Institute (NHLBI)	Phase 3	To measure the effects of lipid-lowering drugs and/or antioxidant vitamins on progression or regression of coronary heart disease as measured by quantitative angiography in patients with low high density lipoprotein (HDL) cholesterol.
NCT00000553	HDL-Atherosclerosis Treatment Study (HATS)	Completed	University of Washington	Phase 3	To measure the effects of lipid-lowering drugs and/or antioxidant vitamins on progression or regression of coronary heart disease as measured by quantitative angiography in patients with low high density lipoprotein (HDL) cholesterol.
NCT00000599	Cholesterol-Lowering Atherosclerosis Study (CLAS)	Completed	National Heart, Lung, and Blood Institute (NHLBI)	Phase 3	To determine whether combined therapy with the lipid lowering agents colestipol hydrochloride plus niacin would produce significant change in coronary, carotid, and femoral artery atherosclerosis and coronary bypass graft lesions as determined by angiography. Also, to determine possible correlations between lesion changes and plasma lipid and lipoprotein cholesterol levels and to explore interrelationships of atherosclerosis change in femoral, coronary, and carotid arteries.
Trial ID	Title	Status	Sponsor	Phase	Summary